JonathanEdwardsDowellMD

Oncology • Dallas, TX

Associate Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to view full profile

Dr. Dowell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dowell's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-2615

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1993 - 1996
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1993

Certifications & Licensure

TX State Medical License 1994 - 2025
TN State Medical License 1999 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Super Doctor SuperDoctors.com

Clinical Trials

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Start of enrollment: 2006 Jun 01
Completed
Phase 3
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma Start of enrollment: 2006 Feb 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Start of enrollment: 2010 Apr 12
Completed
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Concurrent and consolidative carboplatin plus nab-paclitaxel or paclitaxel in locally advanced NSCLC A multicenter, randomized clinical trial.
Yuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, Kenneth D Westover, Jonathan E Dowell
International Journal of Radiation Oncology, Biology, Physics. 2025-02-06
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Margaret Stalker, Connor B Grady, Alex Watts, Wei-Ting Hwang, Krishna Chandrasekhara
JTO Clinical and Research Reports. 2025-01-01
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brie...
Yuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, Kenneth D Westover, Sawsan Rashdan
International Journal of Radiation Oncology, Biology, Physics. 2025-01-01

Journal Articles

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases
David E Gerber, Jonathan E Dowell, Clinical Lung Cancer

Authored Content

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesNovember 2018

Press Mentions

Medical Student Training to Tackle Health Disparities with Language Skills ProgramJuly 15th, 2021
Double-Drug Strategy Blocks Escape Route for Most Lung CancersApril 5th, 2018
Texas Researchers Summarize Promising Research on New Mesothelioma Drug, According to Surviving MesotheliomaMay 2nd, 2017
Join now to see all